News
The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, ...
Kenvue (KVUE), the company behind Tylenol and Neutrogena, announced that Thibaut Mongon had left the company, naming Kirk ...
Kenvue has five brands that generate over $1 billion in sales—Johnson’s, Neutrogena, Listerine, Tylenol, and Aveeno—as well as a number of brands that generate over $400 million in sales: Nicorette, ...
Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...
We believe Perrigo is in fine financial health. At the end of 2024, the company had roughly $560 million in cash and equivalents with about $3.3 billion in long-term debt. Its balance sheet was in a ...
Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...
4d
MarketBeat on MSNJNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is NowAfter years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...
Asian shares are trading mostly lower as worries about President Donald Trump’s latest updates to his tariffs weighed on ...
In a testament to its enduring strength and adaptive strategy, Johnson & Johnson (NYSE: JNJ) today announced a strong ...
“The Board’s strategic review is underway, and we are considering a broad range of potential alternatives, including ways to ...
Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...
J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results